ATE531389T1 - Lipid- und distickstoffoxidverbindung als hilfsmittel zur erhöhung der impfstoffeffizienz - Google Patents

Lipid- und distickstoffoxidverbindung als hilfsmittel zur erhöhung der impfstoffeffizienz

Info

Publication number
ATE531389T1
ATE531389T1 AT06710759T AT06710759T ATE531389T1 AT E531389 T1 ATE531389 T1 AT E531389T1 AT 06710759 T AT06710759 T AT 06710759T AT 06710759 T AT06710759 T AT 06710759T AT E531389 T1 ATE531389 T1 AT E531389T1
Authority
AT
Austria
Prior art keywords
acid
antigen
adjuvant
lipid
tool
Prior art date
Application number
AT06710759T
Other languages
English (en)
Inventor
Anne Grobler
Abraham Frederik Kotze
Original Assignee
Univ Northwest
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwest filed Critical Univ Northwest
Application granted granted Critical
Publication of ATE531389T1 publication Critical patent/ATE531389T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT06710759T 2005-01-28 2006-01-26 Lipid- und distickstoffoxidverbindung als hilfsmittel zur erhöhung der impfstoffeffizienz ATE531389T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA200500856 2005-01-28
PCT/IB2006/050286 WO2006079989A2 (en) 2005-01-28 2006-01-26 Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines

Publications (1)

Publication Number Publication Date
ATE531389T1 true ATE531389T1 (de) 2011-11-15

Family

ID=36608667

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06710759T ATE531389T1 (de) 2005-01-28 2006-01-26 Lipid- und distickstoffoxidverbindung als hilfsmittel zur erhöhung der impfstoffeffizienz

Country Status (10)

Country Link
US (2) US20090010964A1 (de)
EP (1) EP1843787B1 (de)
JP (1) JP5159322B2 (de)
CN (1) CN101123982B (de)
AT (1) ATE531389T1 (de)
CA (1) CA2596920C (de)
DK (1) DK1843787T3 (de)
ES (1) ES2375267T3 (de)
WO (1) WO2006079989A2 (de)
ZA (1) ZA200608016B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006079989A2 (en) 2005-01-28 2006-08-03 North-West University Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
US20100297249A1 (en) * 2007-07-05 2010-11-25 North-West University Enhancement of the efficacy of therapeutic proteins
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2018225785A1 (ja) * 2017-06-06 2018-12-13 株式会社Ａｔｏｍｉｓ ワクチン組成物
CN111936161B (zh) 2018-01-02 2024-06-18 克洛里斯生物科学有限公司 作为癌症的预防性和诊疗性治疗的ipsc基疫苗
KR20240075776A (ko) 2021-06-01 2024-05-29 클로리스 바이오사이언시스 인코포레이티드 유도 만능 줄기 세포-기반 암 백신
CN116139266B (zh) * 2023-04-14 2023-07-14 清华大学 长链不饱和脂肪酸在制备用于灭活疫苗的免疫增强剂中的用途
WO2025155909A1 (en) * 2024-01-19 2025-07-24 Hillhurst Biopharmaceuticals, Inc. Solution of nitrous oxide for the treatment of disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB425406A (en) * 1933-06-07 1935-03-07 Vincent Gregory Walsh Improvements in or relating to the manufacture of medical preparations of bacterial toxins
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
JPH04279523A (ja) * 1991-01-11 1992-10-05 Nisshin Flour Milling Co Ltd 免疫賦活油脂加工品
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
JPH06247849A (ja) * 1993-02-25 1994-09-06 Kao Corp 免疫増強剤
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
JPH09121766A (ja) * 1995-10-31 1997-05-13 Meiji Milk Prod Co Ltd ｎ−６系列／ｎ−３系列脂肪酸比率 を調整した乳児用食品
NZ322588A (en) * 1995-11-13 1999-01-28 Pitmy Int Nv An administration medium containing nitrous oxide for use in conjunction with analgesics, anti-inflammatories and anti-pyretics to enhance their action
SE9602280D0 (sv) * 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
US6696089B2 (en) * 1998-09-03 2004-02-24 Board Of Regents Of The University Of Nebraska Nanogel networks including polyion polymer fragments and biological agent compositions thereof
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
SE9900495D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
SE9900496D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
JP2001029010A (ja) * 1999-07-26 2001-02-06 Snow Brand Milk Prod Co Ltd 栄養組成物
JP2001245686A (ja) * 1999-12-27 2001-09-11 Osaka City 脂肪酸低級アルコールエステルの製造方法
FR2804026B1 (fr) * 2000-01-21 2004-06-11 Merial Sas Vaccination contre l'herpesvirose canine et vaccins
CN100531799C (zh) * 2000-07-19 2009-08-26 西北大学 增强抗感染剂作用的制剂和方法
DE60143058D1 (de) * 2000-07-19 2010-10-21 Univ Northwest Transport von nukleinsäuresubstanzen
US7033813B2 (en) * 2001-09-05 2006-04-25 Trevor P Castor Inactivated vaccines for aids and other infectious diseases
CN1391954A (zh) * 2002-07-09 2003-01-22 新疆大学生命科学与技术学院 增强核酸疫苗免疫的组合物及其生产方法和使用方法
WO2006079989A2 (en) 2005-01-28 2006-08-03 North-West University Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines

Also Published As

Publication number Publication date
ES2375267T3 (es) 2012-02-28
ZA200608016B (en) 2008-09-25
CA2596920C (en) 2015-05-05
CN101123982B (zh) 2015-06-17
HK1118013A1 (en) 2009-01-30
CN101123982A (zh) 2008-02-13
DK1843787T3 (da) 2012-02-20
CA2596920A1 (en) 2006-08-03
EP1843787B1 (de) 2011-11-02
WO2006079989A2 (en) 2006-08-03
US20140178431A1 (en) 2014-06-26
US20090010964A1 (en) 2009-01-08
JP2008528570A (ja) 2008-07-31
EP1843787A2 (de) 2007-10-17
JP5159322B2 (ja) 2013-03-06
US9585955B2 (en) 2017-03-07
WO2006079989A3 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
NZ608755A (en) Plant support formulation, vehicle for the delivery and translocation of phytologically beneficial substances and compositions containing same
Yang et al. Enzymatic enrichment of n-3 polyunsaturated fatty acid glycerides by selective hydrolysis
Tang et al. Study on supercritical extraction of lipids and enrichment of DHA from oil-rich microalgae
KR100918891B1 (ko) 크립테코디늄 속으로 부터의 항산화 추출물의 생산 및 용도
KR101943661B1 (ko) 리파아제에 의한 고도 불포화 지방산 함유 유지의 제조 방법
DK1476171T3 (da) Transport af nukleinsyresubstanser
ATE384518T1 (de) Zusammensetzungen enthaltend phytosterol- und policosanolester von fettsäuren zur herabsetzung des cholesterol- und triglyceridspiegels
JP2010196060A5 (de)
Zhang et al. Concentration of omega-3 polyunsaturated fatty acids from oil of Schizochytrium limacinum by molecular distillation: optimization of technological conditions
US9918953B2 (en) Composition containing eicosapentaenoic acid alkyl ester, and method for producing same
AR071128A1 (es) Metodo para producir gliceridos monoinsaturados
DK1843787T3 (da) Kombination af lipider og dinitrogenoxid som hjælpestof til forøgelse af vacciners virkningsgrad
RU2013150594A (ru) Способ автокаталитической этерификации жирных кислот
WO2002005850A3 (en) Enhancement of the action of anti-infective agents
Patel et al. Novel biorefinery approach aimed at vegetarians reduces the dependency on marine fish stocks for obtaining squalene and docosahexaenoic acid
DE602006008811D1 (de) Verfahren zur herstellung von fettsäureethylestern aus triglyceriden und alkoholen
KR20210099631A (ko) 초장쇄 지방산 조성물
AR076184A1 (es) Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo lipidico. metodo.
CL2022003599A1 (es) Procedimiento de aislamiento de lípidos a partir de una biomasa que contiene lípidos
WO2020050303A1 (ja) リパーゼ加水分解反応を用いる高度不飽和脂肪酸含有グリセリドの製造方法
ATE453409T1 (de) Entzündungshemmende fettalkohole und fettsäureester als antigenträger
JPWO2017038860A1 (ja) 遊離多価不飽和脂肪酸含有組成物及びその製造方法
AR122837A1 (es) Composiciones de ácidos grasos poliinsaturados enriquecidos con dha
JP2018082676A (ja) 構造油脂の製造方法
JP2007089522A5 (de)